HomeCompareDNMDX vs JNJ

DNMDX vs JNJ: Dividend Comparison 2026

DNMDX yields 7.18% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DNMDX wins by $12.1K in total portfolio value
10 years
DNMDX
DNMDX
● Live price
7.18%
Share price
$29.05
Annual div
$2.09
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.2K
Annual income
$1,132.82
Full DNMDX calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — DNMDX vs JNJ

📍 DNMDX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDNMDXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DNMDX + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DNMDX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DNMDX
Annual income on $10K today (after 15% tax)
$610.42/yr
After 10yr DRIP, annual income (after tax)
$962.90/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, DNMDX beats the other by $259.28/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DNMDX + JNJ for your $10,000?

DNMDX: 50%JNJ: 50%
100% JNJ50/50100% DNMDX
Portfolio after 10yr
$26.1K
Annual income
$980.30/yr
Blended yield
3.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

DNMDX
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DNMDX buys
0
JNJ buys
0
No recent congressional trades found for DNMDX or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDNMDXJNJ
Forward yield7.18%3.36%
Annual dividend / share$2.09$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$32.2K$20.0K
Annual income after 10y$1,132.82$827.78
Total dividends collected$9.3K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DNMDX vs JNJ ($10,000, DRIP)

YearDNMDX PortfolioDNMDX Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,418$718.14$10,676$355.77+$742.00DNMDX
2$12,984$766.34$11,407$389.39+$1.6KDNMDX
3$14,707$814.41$12,198$426.53+$2.5KDNMDX
4$16,599$862.15$13,056$467.62+$3.5KDNMDX
5$18,670$909.39$13,987$513.12+$4.7KDNMDX
6$20,933$955.95$14,998$563.56+$5.9KDNMDX
7$23,400$1,001.69$16,098$619.52+$7.3KDNMDX
8$26,084$1,046.49$17,295$681.69+$8.8KDNMDX
9$29,000$1,090.23$18,599$750.82+$10.4KDNMDX
10$32,163$1,132.82$20,022$827.78+$12.1KDNMDX

DNMDX vs JNJ: Complete Analysis 2026

DNMDXStock

The sub-adviser seeks to achieve attractive absolute returns by utilizing an event driven strategy across a diversified set of equities while actively managing risk to preserve capital, minimize volatility, and maintain liquidity. The sub-adviser generally seeks to accomplish this objective by investing in equities (including common stock, initial public offerings (“IPOs”) and other new issues) and equity-related securities (including preferred stock, options, swaps, forwards and warrants) across a diversified range of industries.

Full DNMDX Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this DNMDX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DNMDX vs SCHDDNMDX vs JEPIDNMDX vs ODNMDX vs KODNMDX vs MAINDNMDX vs ABBVDNMDX vs MRKDNMDX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.